BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM $310M
1-Year Return
6.98%
This Quarter Return
-13.36%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$360M
AUM Growth
-$141M
(-28%)
Cap. Flow
-$67.6M
Cap. Flow
% of AUM
-18.8%
Top 10 Holdings %
Top 10 Hldgs %
67.99%
Holding
55
New
10
Increased
7
Reduced
8
Closed
14
Top Buys
| 1 |
Context Therapeutics
CNTX
|
+$10.3M |
| 2 |
Viking Therapeutics
VKTX
|
+$5.04M |
| 3 |
Starwood Property Trust
STWD
|
+$4.29M |
| 4 |
Pyxis Oncology
PYXS
|
+$3.46M |
| 5 |
Tourmaline Bio
TRML
|
+$3.45M |
Top Sells
| 1 |
Robinhood
HOOD
|
+$54M |
| 2 |
Cullinan Oncology
CGEM
|
+$15.3M |
| 3 |
enGene Holdings Inc. Warrants
ENGNW
|
+$5.47M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$5.02M |
| 5 |
Dell
DELL
|
+$4.71M |
Sector Composition
| 1 | Healthcare | 71.57% |
| 2 | Technology | 17.92% |
| 3 | Financials | 8.96% |
| 4 | Real Estate | 1.19% |
| 5 | Industrials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cullinan Oncology
CGEM
$372M
| $35.7M | 9.94% |
2,049,172
-875,670
| -30% | -$15.3M |
|
2
Pliant Therapeutics
PLRX
$93.9M
| $32.3M | 8.98% |
3,004,199
| – | – |
|
3
Blue Owl Capital
OBDC
$7B
| $31.4M | 8.74% |
2,045,070
| – | – |
|
4
Klaviyo
KVYO
$9.88B
| $29.8M | 8.29% |
1,198,270
| – | – |
|
5
Larimar Therapeutics
LRMR
$342M
| $28M | 7.78% |
3,859,468
-135,000
| -3% | -$979K |
|
|
6
enGene Holdings
ENGN
$310M
| $23.1M | 6.43% |
2,449,827
-11,523
| -0.5% | -$109K |
|
|
7
Tourmaline Bio
TRML
$1.23B
| $22.1M | 6.14% |
1,715,401
+268,000
| +19% | +$3.45M |
|
8
EverCommerce
EVCM
$2.12B
| $18M | 5.01% |
1,641,929
| – | – |
|
|
SLRN
9
DELISTED
ACELYRIN
SLRN
| $12.9M | 3.59% |
2,926,028
+100,000
| +4% | +$441K |
|
10
Repare Therapeutics
RPTX
$74.7M
| $11.1M | 3.1% |
3,372,499
+250,000
| +8% | +$825K |
|
11
Ultragenyx Pharmaceutical
RARE
$2.84B
| $11M | 3.07% |
268,238
| – | – |
|
|
12
Context Therapeutics
CNTX
$76.1M
| $10.3M | 2.88% |
+5,161,290
| New | +$10.3M |
|
13
Disc Medicine
IRON
$2.1B
| $9.7M | 2.7% |
215,260
+60,000
| +39% | +$2.7M |
|
14
Toast
TOST
$23.3B
| $8.31M | 2.31% |
322,578
| – | – |
|
|
ETWO
15
DELISTED
E2open Parent Holdings
ETWO
| $7.41M | 2.06% |
1,650,943
| – | – |
|
16
Keros Therapeutics
KROS
$642M
| $7.2M | 2% |
157,633
-15,000
| -9% | -$686K |
|
|
IMA
17
ImageneBio, Inc. Common Stock
IMA
$95.3M
| $6.75M | 1.88% |
340,927
+16,667
| +5% | +$330K |
|
18
Sagimet Biosciences
SGMT
$202M
| $5.72M | 1.59% |
1,673,877
| – | – |
|
19
Mineralys Therapeutics
MLYS
$2.9B
| $5.27M | 1.47% |
450,339
-90,741
| -17% | -$1.06M |
|
|
20
Viking Therapeutics
VKTX
$2.66B
| $5.04M | 1.4% |
+95,000
| New | +$5.04M |
|
|
INZY
21
DELISTED
Inozyme Pharma
INZY
| $5M | 1.39% |
1,120,027
-150,000
| -12% | -$669K |
|
|
22
Starwood Property Trust
STWD
$7.41B
| $4.29M | 1.19% |
+226,456
| New | +$4.29M |
|
|
23
Pyxis Oncology
PYXS
$127M
| $3.46M | 0.96% |
+1,046,025
| New | +$3.46M |
|
|
MREO
24
Mereo BioPharma
MREO
$280M
| $3.23M | 0.9% |
+897,809
| New | +$3.23M |
|
25
Aquestive Therapeutics
AQST
$589M
| $2.96M | 0.82% |
1,140,000
+265,000
| +30% | +$689K |
|